Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50750 |
Name | splenic marginal zone lymphoma |
Definition | A marginal zone B-cell lymphocyte located_in the spleen comprised of B-cells in place of white pulp. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma marginal zone lymphoma splenic marginal zone lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF mutant | N/A | splenic marginal zone lymphoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03322865 | Phase II | Obinutuzumab | Obinutuzumab in Marginal Zone Lymphoma | Active, not recruiting | DEU | 0 |
NCT03474744 | Phase II | Copanlisib + Rituximab | Copanlisib and Rituximab in Marginal Zone Lymphoma Patients | Active, not recruiting | DEU | AUT | 0 |
NCT03601819 | Phase I | Pacritinib | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | Terminated | USA | 0 |
NCT03696784 | Phase I | Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | Recruiting | USA | 0 |
NCT03697512 | Phase II | Ibrutinib + Rituximab | MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (MALIBU) | Active, not recruiting | ITA | FRA | CHE | BEL | 1 |
NCT04223765 | Phase I | Bendamustine + CAR.k.28 cells + Fludarabine CAR.k.28 cells + Cyclophosphamide + Fludarabine | Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04680052 | Phase III | Lenalidomide + Rituximab Lenalidomide + Rituximab + Tafasitamab-cxix | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND) | Active, not recruiting | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 5 |
NCT04842877 | Phase II | DS-3201b | Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma | Active, not recruiting | FRA | BEL | 0 |
NCT05338346 | Phase I | ATG-018 | A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM) | Terminated | AUS | 0 |
NCT05424822 | Phase I | JNJ-80948543 | A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | POL | ISR | FRA | DNK | AUS | 2 |
NCT05735834 | Phase III | Rituximab Rituximab + Zanubrutinib | Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients (RITZ) | Recruiting | SWE | NOR | ITA | GBR | FRA | ESP | DNK | CHE | AUT | 0 |
NCT06006117 | Phase III | Lenalidomide + Rituximab Lenalidomide + Mosunetuzumab-axgb Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab | Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma | Recruiting | FRA | 0 |
NCT06300528 | Phase II | Pemigatinib | Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma | Not yet recruiting | USA | 0 |
NCT06350318 | Phase II | Rituximab + Zanubrutinib | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | Recruiting | USA | 0 |
NCT06378190 | Phase Ib/II | TranspoCART19 | Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19) | Recruiting | ESP | 0 |